32
Participants
Start Date
January 21, 2016
Primary Completion Date
January 10, 2018
Study Completion Date
January 24, 2018
ALO-02
Oral/Capsule, twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 4 week Maintenance Treatment duration.
East Carolina University Brody School of Medicine(ECU), Greenville
Leo Jenkins Cancer Center Pharmacy, Greenville
Medical University of South Carolina Children's Hospital, Charleston
Medical University of South Carolina, Investigational Drugs Services, Charleston
Medical University of South Carolina, Rutledge Tower, Pediatric Clinic, Charleston
Medical University of South Carolina, SCTR Research Nexus, Charleston
University of Illinois at Chicago Clinical Research Center, Chicago
University of Illinois Hospital and Health Sciences Systems, Chicago
University of Illinois Hospital at the Medical Center, Chicago
Road Runner Research, Ltd, San Antonio
Children's Hopsital Los Angeles, Los Angeles
Children's Hospital Of Los Angeles - University Of Southern California School Of Medicine, Los Angeles
Research Center For Clinical Studies-West, Inc., Lancaster
Shriners Hospitals For Children Northern California, Sacramento
UC Davis Health Attn: Peter Trovitch, PharmD, Sacramento
University of California Davis, Sacramento
Lead Sponsor
Pfizer
INDUSTRY